Fig. 6: Metastatic CRC patients with a high PIANOS score were more sensitive to bevacizumab.
From: Personalized risk stratification in colorectal cancer via PIANOS system
A, B Gene set enrichment analysis (GSEA) plots of angiogenesis(CIT p = 7.36 × 10−9, TCGA p = 0.01, ACICAM p = 1.93 × 10−7, COCC p = 5.92 × 10−10) and WP_angiogeneis(CIT p = 2.70 × 10−4, TCGA p = 0.07, ACICAM p = 1.00 × 10−5, COCC p = 2.65 × 10−3) pathway(low- vs high-risk). P values from a two-sided permutation test. C, D Violin plots of predicted endothelial cells (CIT p = 1.92 × 10−9, TCGA p = 0.702, ACICAM p = 3.06 × 10−7, COCC p = 9.71 × 10−11), and VEGFA expression(CIT p = 7.71 × 10−3, TCGA p = 1.11 × 10−7, ACICAM p = 1.06 × 10−4, COCC p = 1.17 × 10−8) by PIANOS risk group. Datasets: CIT (n = 562), COCC (n = 968), TCGA (n = 618), ACICAM (n = 348). E–G t-distributed stochastic neighbor embedding (tSNE) plot showing cell clusters (all cells and stromal cells) in GSE178341. H, I Violin plots showing endothelial cells in all cells(p = 0.0013) and VEGFA (+) cells in endothelial cells (p = 6.3 × 10−4) by PIANOS risk group in GSE178341 (n = 62). J, K Kaplan–Meier curves for overall survival (OS) by bevacizumab status in COCC patients stratified by VEGFA expression (high and low). L, M Kaplan–Meier curves for OS by bevacizumab status in COCC patients stratified by PIANOS risk (high- and low-risk). N, O Representative CT images of high-risk patients before and after treatment. N Patient 7 (bevacizumab-treated) showing reduced liver metastases. O Patient 8 (bevacizumab-untreated) showing rapid progression. Unless otherwise stated, P-values for violin plots (C, D, H, I) were calculated using a two-sided Wilcoxon rank-sum test. P values for Kaplan–Meier curves (J–M) from two-sided log-rank test. Box plots: median (center), 25th/75th percentiles (box), whiskers (1.5xIQR, outliers not shown). *p < 0.05, **p < 0.01, ***p < 0.001 (C, D, H, I). Source data are provided as a Source Data file.
